RIGL
$2.47
Rigel Pharmaceuticals
($.05)
(1.98%)
RIGL
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.11)
Revenue:  $17.43 Mil
Thursday
Feb 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 5, 2019

What do you expect when RIGL reports earnings?
Beat
Meet
Miss

Where is RIGL's stock price going from here?
Up
Flat
Down
Stock chart of RIGL
Analysts
Summary of analysts' recommendations for RIGL
Score
Grade
Pivots
Resistance
$2.84
$2.75
$2.64

$2.55

Support
$2.44
$2.35
$2.24
Tweet
Growth
Description
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Peers
Regeneron PharmaceuticalsBioMarin PharmaceuticalInterCeptVertex PharmaceuticalsMylanZoetisJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEndo International plc